ライフサイエンスコーパス: pomalidomide

1 c activity of another immunomodulatory drug, pomalidomide.

2 oidosis responding to salvage treatment with pomalidomide.

3 with a higher affinity than lenalidomide or pomalidomide.

4 nation of immunotherapy with lenalidomide or pomalidomide.

5 the immunomodulatory drugs lenalidomide and pomalidomide.

6 mplex bound to thalidomide, lenalidomide and pomalidomide.

7 e sensitive or resistant to lenalidomide and pomalidomide.

8 cebo, pomalidomide (2 mg/d) plus prednisone, pomalidomide (0.5 mg/d) plus prednisone, and prednisone

9 Three patients received pomalidomide 2 mg/d with no dose-limiting toxicity.

10 n study, four treatment arms were evaluated: pomalidomide (2 mg/d) plus placebo, pomalidomide (2 mg/d

11 aluated: pomalidomide (2 mg/d) plus placebo, pomalidomide (2 mg/d) plus prednisone, pomalidomide (0.5

12 16 mg/kg at the recommended dosing schedule, pomalidomide 4 mg daily for 21 days of each 28-day cycle

13 s of pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, and dexamethasone 4

14 Patients were randomized (1:1) to receive pomalidomide 4 mg on days 1 to 21 of a 28-day cycle in c

15 data from other phase 2 trials, suggest that pomalidomide 4 mg per day on days 1 to 21 of 28 with dex

16 Pomalidomide 4 mg per day on days 1 to 21 of each 28-day

17 Pomalidomide 4 mg was given on days 1-21 of 28-day cycle

18 was dose level 1 (carfilzomib 20/27 mg/m(2), pomalidomide 4 mg, dexamethasone 40 mg).

19 ned the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 2

20 In phase 1, dose level 1 consisted of pomalidomide (4 mg by mouth on days 1 to 21), IV or subc

21 Pomalidomide (4 mg) was given orally on days 1 to 21 (ar

22 Blood, Dulmovits and colleagues report that pomalidomide, a drug approved by the US Food and Drug Ad

23 Pomalidomide, a third-generation immunomodulatory drug,

24 Pomalidomide acted early by transiently delaying erythro

25 o our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose d

26 We evaluated pomalidomide, an oral immune modulatory agent, in patien

27 rial, we assessed the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with A

28 Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated i

29 Combination studies using pomalidomide and dexamethasone are now underway.

30 The combination of pomalidomide and dexamethasone can be safely administere

31 udy assessing two different dose regimens of pomalidomide and dexamethasone in advanced MM.

32 eagues(2) publish two different trials using pomalidomide and dexamethasone in patients with relapsed

33 ed in 44 refractory MM patients treated with pomalidomide and dexamethasone therapy in whom low IKZF1

34 e believe to be a new mechanism of action of pomalidomide and lenalidomide and support the hypothesis

35 e new insights on the mechanism of action of pomalidomide and lenalidomide in the regulation of gene

36 on our findings, we propose a model in which pomalidomide and lenalidomide modify the chromatin struc

37 We tested the effect of Pomalidomide and Lenalidomide on angiogenesis, teratogen

38 demethylase-1 (LSD1) silencing reduced both pomalidomide and lenalidomide up-regulation of p21(WAF-1

39 ves of thalidomide (IMiD compounds), such as pomalidomide and lenalidomide, are highly active in mult

40 The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be

41 Pomalidomide and low-dose dexamethasone (PomDex) is stan

42 The combination of pomalidomide and low-dose dexamethasone is extremely act

43 Using pomalidomide and primary human monocytes, we report that

44 etermine the maximum tolerated dose (MTD) of pomalidomide and to explore its efficacy when combined w

45 When combined with hydroxyurea, pomalidomide and, to a lesser extent, lenalidomide were

46 erapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label,

47 Pembrolizumab, pomalidomide, and low-dose dexamethasone have acceptable

48 We conclude that pomalidomide appears to be a valuable drug covering an u

49 unomodulatory drugs (IMiDs) lenalidomide and pomalidomide are Food and Drug Administration-approved d

50 and its structural analogs lenalidomide and pomalidomide are highly effective in treating clinical i

51 Lenalidomide and pomalidomide are members of a class of immunomodulators

52 These findings support further evaluation of pomalidomide as a novel therapy for SCD.

53 This work has implications for Pomalidomide as a treatment for conditions Thalidomide a

54 These findings support the evaluation of pomalidomide as an innovative new therapy for beta-hemog

55 Pomalidomide at doses of 2 or 4 mg/d has demonstrated ex

56 t to hydroxyurea's myelosuppressive effects, pomalidomide augmented erythropoiesis and preserved bone

57 The drugs lenalidomide and pomalidomide bind to the protein cereblon, directing the

58 mum tolerated doses, safety, and efficacy of pomalidomide, bortezomib, and dexamethasone (PVD) combin

59 how pharmacologic agents (eg, lenalidomide, pomalidomide, bortezomib, and dexamethasone) and autolog

60 me highly resistant to both lenalidomide and pomalidomide, but not to the unrelated drugs bortezomib,

61 han double that observed with decitabine and pomalidomide; butyrate had an intermediate effect wherea

62 ently developed and offer new possibilities (pomalidomide, carfilzomib and ixazomib, panobinostat, el

63 Pomalidomide-cyclophosphamide-prednisone is safe and eff

64 over, multiple myeloma patients treated with pomalidomide demonstrated increased in vivo gamma-globin

65 ination with weekly dexamethasone (arm B) or pomalidomide, dexamethasone, and cyclophosphamide (PomCy

66 tinuous or intermittent dosing strategies of pomalidomide/dexamethasone in lenalidomide-refractory my

67 We found that Pomalidomide, displays a high degree of cell specificity

68 he clinical and pharmacodynamics analysis of pomalidomide dosing strategies in multiple myeloma (MM)

69 inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plu

70 onal or investigational (eg, JAK inhibitors, pomalidomide) drug therapy, allogenic stem cell transpla

71 The pomalidomide effect on actin cytoskeleton was blocked by

72 the activation of Rho GTPases, we found that pomalidomide enhanced F-actin formation, stabilized micr

73 An additional analog, Pomalidomide, has recently been licensed for treatment o

74 Lenalidomide and pomalidomide have both been evaluated clinically for the

75 idomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of haemato

76 Pomalidomide in combination with weekly dexamethasone (P

77 and cereblon/ikaros in antitumor effects of pomalidomide in vivo is unknown.

78 e selectively and differentially affected by pomalidomide including BCL11A, SOX6, IKZF1, KLF1, and LS

79 Here, we report that pomalidomide induced a fetal-like erythroid differentiat

80 We found that 8 weeks of treatment with pomalidomide induced modest increases of HbF with simila

81 Pomalidomide induced poly-functional T-cell activation,

82 hat the activation of RhoA was essential for pomalidomide-induced interleukin-2 expression in T cells

83 Notably, the pomalidomide-induced reprogramming was conserved in hema

84 In addition, they show that pomalidomide induces HbF in differentiating erythroid ce

85 Pomalidomide is a new IMiD with high in vitro potency.

86 Pomalidomide is a potent structural analog of thalidomid

87 We demonstrate that in vivo embryonic assays Pomalidomide is a significantly more potent anti-inflamm

88 Conclusion Pomalidomide is well tolerated and active in KS regardle

89 e antimyeloma cellular immunity generated by pomalidomide, leading to improved clinical responses.

90 These data demonstrate that pomalidomide leads to strong and rapid immunomodulatory

91 Pomalidomide led to rapid decline in Ikaros in T and NK

92 In preclinical studies, pomalidomide mediated both direct antitumor effects and

93 inding transcription factors are involved in pomalidomide-mediated up-regulation of p21(WAF-1).

94 thalidomide (n=42), lenalidomide (n=18), or pomalidomide (n=18).

95 We investigated the effects of pomalidomide on erythropoiesis and hemoglobin synthesis

96 investigated the effects of lenalidomide and pomalidomide on erythropoiesis and hemoglobin synthesis.

97 15, and 16 (starting dose of 20/27 mg/m(2)), pomalidomide once daily on days 1 to 21 (4 mg as the ini

98 Further, we showed that in Swiss 3T3 cells, pomalidomide only activated RhoA, not Rac1 or Cdc42, and

99 xic activity of anti-MM agents lenalidomide, pomalidomide or dexamethasone.

100 utic value of new drugs (eg, JAK inhibitors, pomalidomide) or allogeneic stem-cell transplantation.

101 Pomalidomide overcomes resistance in myeloma refractory

102 present the largest trial to date evaluating pomalidomide plus low-dose dexamethasone in patients wit

103 TRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest

104 2 study assessed the efficacy and safety of pomalidomide (POM) with/without low-dose dexamethasone (

105 other day, for 6 28-day cycles, followed by pomalidomide-prednisone maintenance therapy.

106 and primary human monocytes, we report that pomalidomide rapidly and selectively activated RhoA and

107 ata reveal the molecular mechanisms by which pomalidomide reactivates fetal hemoglobin, reinforcing i

108 drugs such as thalidomide, lenalidomide, and pomalidomide, recognizes an acetyl degron of GS, resulti

109 Recent reports demonstrated that pomalidomide reduced or eliminated transfusion requireme

110 modulatory drugs, including lenalidomide and pomalidomide represent a novel class of small molecule a

111 ew agents, such as the third-generation IMiD pomalidomide, the second-generation PIs carfilzomib and

112 Pomalidomide therapy at 0.5 or 2 mg/d with or without an

113 idomide and its derivatives lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recen

114 nations adding 1 of these new agents (except pomalidomide) to the RD or VD regimens were superior to

115 genetic ablation of IKZF1 did not phenocopy pomalidomide treatment.

116 lenalidomide and support the hypothesis that pomalidomide, used alone or in combination with hydroxyu

117 Finally, we demonstrated that pomalidomide was able to regulate the activity of Rho GT

118 Pomalidomide was administered at 2 and 3 mg on days 1 to

119 Pomalidomide was administered continuously and dexametha

120 Pomalidomide was administered for up to 12 28-day treatm

121 Pomalidomide was given at 1 to 2.5 mg/d, cyclophosphamid

122 Pomalidomide was given orally 2 or 4 mg daily with dexam

123 Pomalidomide was shown to be even more effective in refr

124 IKAROS (IKZF1), a known target of pomalidomide, was degraded by the proteasome, but was no

125 the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food

126 t correlation of immune effects triggered by pomalidomide with clinical responses in MM patients.

127 The objectives of a phase 1/2 trial of pomalidomide with dexamethasone for the treatment of lig

128 Response to pomalidomide with or without prednisone was durable (ran

129 opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen

130 unomodulatory drugs (IMiDs) lenalidomide and pomalidomide yield high response rates in patients with